belimumab (Benlysta)

From Aaushi
Jump to navigation Jump to search

Epidemiology

  • may not be effective in people of African descent

Indications

Contraindications

Pregnancy category: C[3]

Dosage

  • 10 mg/kg given as an IV infusion on study days 0, 14, & 28 then every 4 weeks thereafter for a total of 48 weeks[2]

Monitor

Adverse effects

  • risk of infection
  • increased mortality

Mechanism of action

Management

Notes

  • costs at least $35,000 per year (2011)[2]
  • self-injectable belimumab (Benlysta) for SLE FDA-approved July 2017

More general terms

References

  1. 1.0 1.1 FDA NEWS RELEASE: March 9, 2011 FDA approves Benlysta to treat lupus http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm
  2. 2.0 2.1 2.2 Prescriber's Letter 18(5): 2011 Management of Systemic Lupus Erythematosus Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270512&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 3.2 3.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18, 19. American College of Physicians, Philadelphia 2012, 2015, 2018, 2022.
  4. Furie R, Petri M, Zamani O et al A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918-30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22127708
  5. Brooks M FDA Clears Self-injectable Belimumab (Benlysta) for SLE Medscape - Jul 21, 2017. http://www.medscape.com/viewarticle/883270
  6. Garcia A, De Sanctis JB. A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus. Curr Pharm Des. 2016;22(41):6306-6312. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27587201